51
|
Egberts K, Mehler-Wex C, Gerlach M. Therapeutic Drug Monitoring in Child and Adolescent Psychiatry*. PHARMACOPSYCHIATRY 2011; 44:249-53. [DOI: 10.1055/s-0031-1286291] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
52
|
Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Müller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G. AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. PHARMACOPSYCHIATRY 2011; 44:195-235. [PMID: 21969060 DOI: 10.1055/s-0031-1286287] [Citation(s) in RCA: 580] [Impact Index Per Article: 44.6] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Therapeutic drug monitoring (TDM), i. e., the quantification of serum or plasma concentrations of medications for dose optimization, has proven a valuable tool for the patient-matched psychopharmacotherapy. Uncertain drug adherence, suboptimal tolerability, non-response at therapeutic doses, or pharmacokinetic drug-drug interactions are typical situations when measurement of medication concentrations is helpful. Patient populations that may predominantly benefit from TDM in psychiatry are children, pregnant women, elderly patients, individuals with intelligence disabilities, forensic patients, patients with known or suspected genetically determined pharmacokinetic abnormalities or individuals with pharmacokinetically relevant comorbidities. However, the potential benefits of TDM for optimization of pharmacotherapy can only be obtained if the method is adequately integrated into the clinical treatment process. To promote an appropriate use of TDM, the TDM expert group of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) issued guidelines for TDM in psychiatry in 2004. Since then, knowledge has advanced significantly, and new psychopharmacologic agents have been introduced that are also candidates for TDM. Therefore the TDM consensus guidelines were updated and extended to 128 neuropsychiatric drugs. 4 levels of recommendation for using TDM were defined ranging from "strongly recommended" to "potentially useful". Evidence-based "therapeutic reference ranges" and "dose related reference ranges" were elaborated after an extensive literature search and a structured internal review process. A "laboratory alert level" was introduced, i. e., a plasma level at or above which the laboratory should immediately inform the treating physician. Supportive information such as cytochrome P450 substrate- and inhibitor properties of medications, normal ranges of ratios of concentrations of drug metabolite to parent drug and recommendations for the interpretative services are given. Recommendations when to combine TDM with pharmacogenetic tests are also provided. Following the guidelines will help to improve the outcomes of psychopharmacotherapy of many patients especially in case of pharmacokinetic problems. Thereby, one should never forget that TDM is an interdisciplinary task that sometimes requires the respectful discussion of apparently discrepant data so that, ultimately, the patient can profit from such a joint effort.
Collapse
|
53
|
Goldmann K, Kuhlmann S, Gerlach M, Bornträger C. [Removal of the laryngeal mask airway in the post-anesthesia care unit. A means of process optimization?]. Anaesthesist 2011; 60:1002-8. [PMID: 21881929 DOI: 10.1007/s00101-011-1936-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2011] [Revised: 08/03/2011] [Accepted: 08/03/2011] [Indexed: 11/26/2022]
Abstract
BACKGROUND Removal of the laryngeal mask airway in the post-anesthesia care unit could potentially contribute to a faster turnover from one operation to the next. The aim of this study was, therefore, to obtain an insight into the potential time saving and the safety of planned removal of the ProSeal™-LMA (PLMA) in the post-anesthesia care unit. METHODS In this study 120 adult patients with American Society of Anesthesiologists (ASA) classification I-II, age range 18-85 years, undergoing a surgical procedure under general anesthesia in which the PLMA was used were randomly assigned to one of two groups. In group I, the PLMA was removed in the awake patient in the operating room close to the end of the procedure. In group II, the anesthetised but spontaneously breathing patients were moved to the recovery room and the PLMA removed when the patient was awake. The anesthesia technique was standardized [balanced, sevoflurane, fentanyl, bispectral index-guided (BIS) target value=35±5] and identical in both groups until randomization. Patients were breathing room air during transport to the recovery room. Different time intervals as well as the incidence of critical incidents were compared between groups. An oxygen saturation (S(p)O(2)) value <95% was considered a clinically relevant and S(p)O(2) values <90% as clinically critical O(2)-desaturation. RESULTS Removal of the PLMA took place after an average of 4.9±5.1 min in group I and after 19.5±9.6 min in group II. There was no difference in the availability of the anesthetist in the operating room for the following procedure between groups (group I: 12±5.6 min vs. group II: 10.7±4.2 min, p>0.05) despite the fact that patients of group II left the operating room faster (4.9±3.9 min) than patients of group I (7.1±5.1 min, p<0.01). In group II patients were ready for discharge (White score=12) from the recovery room later (13.2±8.2 min) than in group I (3.6±4.8 min, p<0.01). There were no significant differences in other process related time intervals between group I and group II: duration of the operation (113.2±45.9 min vs. 105.3±42.6 min), duration of dressing (5.1±3.7 min vs. 4.6±2.8 min), duration of transport to the recovery room (3.9±1.3 min vs. 3.6±1.3 min) and information at end of surgery by the surgeon (22.5±9.3 min vs. 22.4±10.5 min). The incidence of clinically relevant as well as clinically critical O(2) desaturation at the time of recovery room arrival (S(p)O(2)≤90%) was increased in group II with 33.3% vs. 56.6% and 13.3% vs. 6.7%, p<0.01, respectively. CONCLUSION Planned PLMA removal in the recovery room after BIS-guided balanced anesthesia did not enable the anesthetist to be available earlier for induction of anesthesia in the following patient. Hence the anesthetist could not contribute to a faster turnover of cases. Obviously, with the type of close communication between surgeon and anesthetist dictated by the study protocol (announcement of expected end of surgery by the surgeon 20 min before end of surgery) it is possible for the patient to regain consciousness within a very small time window following the end of surgery. Following this kind of protocol, postponement of removal of the LMA in the recovery room does not seem to be attractive neither from a clinical nor an economic point of view. In contrast, removal of LMA in the recovery room should be restricted to occasional cases with an abrupt end of the operation or prolonged emergence from anesthesia. The obvious risk of hypoxemia necessitates continuous O(2) application and S(p)O(2) monitoring during transport to the recovery room.
Collapse
|
54
|
Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Müller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. PHARMACOPSYCHIATRY 2011; 44:195-235. [PMID: 22053351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Therapeutic drug monitoring (TDM), i. e., the quantification of serum or plasma concentrations of medications for dose optimization, has proven a valuable tool for the patient-matched psychopharmacotherapy. Uncertain drug adherence, suboptimal tolerability, non-response at therapeutic doses, or pharmacokinetic drug-drug interactions are typical situations when measurement of medication concentrations is helpful. Patient populations that may predominantly benefit from TDM in psychiatry are children, pregnant women, elderly patients, individuals with intelligence disabilities, forensic patients, patients with known or suspected genetically determined pharmacokinetic abnormalities or individuals with pharmacokinetically relevant comorbidities. However, the potential benefits of TDM for optimization of pharmacotherapy can only be obtained if the method is adequately integrated into the clinical treatment process. To promote an appropriate use of TDM, the TDM expert group of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) issued guidelines for TDM in psychiatry in 2004. Since then, knowledge has advanced significantly, and new psychopharmacologic agents have been introduced that are also candidates for TDM. Therefore the TDM consensus guidelines were updated and extended to 128 neuropsychiatric drugs. 4 levels of recommendation for using TDM were defined ranging from “strongly recommended” to “potentially useful”. Evidence-based “therapeutic reference ranges” and “dose related reference ranges” were elaborated after an extensive literature search and a structured internal review process. A “laboratory alert level” was introduced, i. e., a plasma level at or above which the laboratory should immediately inform the treating physician. Supportive information such as cytochrome P450 substrate and inhibitor properties of medications, normal ranges of ratios of concentrations of drug metabolite to parent drug and recommendations for the interpretative services are given. Recommendations when to combine TDM with pharmacogenetic tests are also provided. Following the guidelines will help to improve the outcomes of psychopharmacotherapy of many patients especially in case of pharmacokinetic problems. Thereby, one should never forget that TDM is an interdisciplinary task that sometimes requires the respectful discussion of apparently discrepant data so that, ultimately, the patient can profit from such a joint eff ort.
Collapse
|
55
|
Klampfl K, Fleischmann Y, Wewetzer C, Pfuhlmann B, Mehler-Wex C, Gerlach M. Therapeutic drug monitoring (TDM) in children and adolescents during sertraline therapy. PHARMACOPSYCHIATRY 2011. [DOI: 10.1055/s-0031-1292290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
56
|
Gerlach M, Kuhn W, Müller T, Winkel R, Lange H, Przuntek H. Increased GABA synthesis in skin fibroblasts of patients with Huntington's disease: a possible role of glutamic acid decarboxylase? Eur J Neurol 2011. [DOI: 10.1111/j.1468-1331.1996.tb00251.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
57
|
Grünblatt E, Schmidt WJ, Scheller DKA, Riederer P, Gerlach M. Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats. J Neural Transm (Vienna) 2010; 118:1717-25. [PMID: 21188436 DOI: 10.1007/s00702-010-0552-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2010] [Accepted: 12/01/2010] [Indexed: 02/04/2023]
Abstract
Continuous dopaminergic treatment is considered to prevent or delay the occurrence of dyskinesia in patients with Parkinson's disease (PD). Rotigotine is a non-ergolinic D(3) > D(2) > D(1) dopamine-receptor agonist for the treatment of PD using a transdermal delivery system providing stable plasma levels. We aimed to investigate the differential influence on gene expression of pulsatile L: -DOPA or rotigotine versus a continuous rotigotine treatment. The gene expression profile within the nigro-striatal system of unilateral 6-hydroxydopamine-lesioned rats was assessed in order to differentiate potential changes in gene expression following the various treatment using Affymetrix microarrays and quantitative RT-PCR. The expression of 15 genes in the substantia nigra and of 11 genes in the striatum was altered under pulsatile treatments inducing dyskinetic motor response, but was unchanged under continuous rotigotine treatment that did not cause dyskinetic motor response. The route of administration of a dopaminergic drug is important for the induction or prevention of motor abnormalities and adaptive gene expressions. The decline of neurotrophin-3 expression under pulsatile administration was considered of particular importance.
Collapse
|
58
|
Berg D, Godau J, Riederer P, Gerlach M, Arzberger T. Microglia activation is related to substantia nigra echogenicity. J Neural Transm (Vienna) 2010; 117:1287-92. [PMID: 21057966 DOI: 10.1007/s00702-010-0504-6] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2010] [Accepted: 10/05/2010] [Indexed: 12/25/2022]
Abstract
Hyperechogenicity of the substantia nigra (SN) is a sensitive marker for Parkinson's disease (PD). Previously, a relation between SN echogenicity and iron as well as neuromelanin content could be described in 60 human brains. In the present study on a subset of 33 brains, SN echogenicity was found to be correlated with microglia activation (ρ = 0.46, p = 0.008) after correction for iron and neuromelanin content. These findings strengthen the hypothesis of a close pathophysiological connection between SN hyperechogenicity and PD pathology.
Collapse
|
59
|
Seipelt I, Guenther E, Baasner S, Blumenstein L, Mueller G, Fensterle J, Engel J, Teifel M, Gerlach M. 98 AEZS-129, an orally active PI3K inhibitor in preclinical development. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71803-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
60
|
Seipelt I, Gerlach M, Baasner S, Blumenstein L, Mueller G, Aicher B, Engel J, Guenther E, Teifel M. 197 AEZS-132, a new orally bioavailable PI3K/Erk inhibitor with antitumor effects. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71902-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
61
|
Klampfl K, Quattländer A, Burger R, Pfuhlmann B, Warnke A, Gerlach M. Case report: intoxication with high dose of long-acting methylphenidate (Concerta(®)) in a suicidal 14-year-old girl. ACTA ACUST UNITED AC 2010; 2:221-4. [PMID: 21432608 DOI: 10.1007/s12402-010-0032-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2010] [Accepted: 08/15/2010] [Indexed: 11/30/2022]
Abstract
A 14-year-old girl with suicidal ideation was presented to the paediatric hospital about 2 h after ingestion of 21 long-acting methylphenidate (MPH) 54-mg tablets (1,134 mg Concerta(®)). At admission signs of sympathomimetic syndrome were observed like agitation, visual hallucinations, slight hypertension, and sinus tachycardia. Treatment included prevention of absorption (30 g activated charcoal orally) and careful observation related to the overstimulation of the sympathic system. Despite the intake of charcoal, the serum concentrations of MPH were 107 and 93 ng/ml 2.5 and 22 h after ingestion of MPH tablets. No support of vital functions was necessary. The girl made a full recovery and was discharged after 3 days of care at the paediatric clinic and referred to the child and adolescent psychiatric department. Exposure to a huge overdose of long-acting MPH exhibited acute sympathomimetic toxicity but no life-threatening symptoms in this patient. Thus this case report suggests that patients intoxicated with high dose long-acting MPH formulations can recover without sequelae when managed properly.
Collapse
|
62
|
Klampfl K, Taurines R, Preuss A, Burger R, Rothenhöfer S, Wewetzer C, Pfuhlmann B, Fegert J, Gerlach M, Mehler-Wex C. Serum Concentrations, Therapeutic Response and Side Effects in Children and Adolescents with Impulsive-Aggressive Symptoms during Risperidone Therapy. PHARMACOPSYCHIATRY 2009; 43:58-65. [DOI: 10.1055/s-0029-1239540] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
63
|
Gerlach M, Beck J, Riederer P, van den Buuse M. P2.111 Anti-dyskinetic effects of flibanserin on levodopa-induced dyskinesia in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Parkinsonism Relat Disord 2009. [DOI: 10.1016/s1353-8020(09)70462-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
64
|
Schmitt AG, Hall FS, Perona M, Ortega G, Hofmann M, Sora I, Uhl GR, Riederer P, Lesch KP, Gerlach M, Grünblatt E. Stress and methylphenidate treatment, both modulate neuronal activity in an animal model for ADHD. PHARMACOPSYCHIATRY 2009. [DOI: 10.1055/s-0029-1240220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
65
|
Double KL, Rowe DB, Carew-Jones FM, Hayes M, Chan DKY, Blackie J, Corbett A, Joffe R, Fung VS, Morris J, Riederer P, Gerlach M, Halliday GM. Anti-melanin antibodies are increased in sera in Parkinson's disease. Exp Neurol 2009; 217:297-301. [PMID: 19289120 DOI: 10.1016/j.expneurol.2009.03.002] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2008] [Revised: 02/22/2009] [Accepted: 03/05/2009] [Indexed: 01/01/2023]
Abstract
An increasing body of research suggests that a number of immune mechanisms play a role in degenerative pathways in Parkinson's disease (PD). In the current work we investigated a posited humoral immune response in this disorder. Sera from PD patients exhibited a significantly enhanced absorbance response on a novel ELISA for anti-melanin antibodies, compared to sera from age-matched control subjects. The enhanced ELISA absorbance response was specific for catecholamine-based melanins and was unrelated to antiparkinsonian dopaminergic medication. Further, the absorbance response was significantly and negatively correlated with disease duration. These data suggest that a specific humoral anti-melanin antibody response is present in PD and is more active in early disease. While the contribution of this novel immune response to the initiation and progression of this disorder is unclear, this finding supports the hypothesis that specific immune responses occurring in PD may respond to therapeutic interventions in this disorder.
Collapse
|
66
|
Paulini KW, Baasner S, Gerlach M, Polymeropoulos EE, Schmidt P, Schuster T, Teifel M, Guenther EG. Development of AEZS-115 (ZEN-019) by Optimization of Structurally Unique, Orally Active, Peptidomimetic GnRH Antagonists. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2009; 611:521-2. [DOI: 10.1007/978-0-387-73657-0_227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
67
|
Klampfl K, Kipp E, Preuss A, Huennerkopf R, Burger R, Rothenhoefer S, Wewetzer C, Fegert J, Mehler-Wex C, Gerlach M. Therapeutic Drug Monitoring in Children and Adolescent Psychiatry – First Results for Atypical Antipsychotic Drugs. PHARMACOPSYCHIATRY 2008. [DOI: 10.1055/s-0028-1088259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
68
|
Gerlach M, Deckert J, Rothenberger A, Warnke A. Pathogenesis and pathophysiology of attention-deficit/hyperactivity disorder: from childhood to adulthood. J Neural Transm (Vienna) 2008; 115:151-3. [DOI: 10.1007/s00702-007-0870-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
69
|
Tribl F, Arzberger T, Riederer P, Gerlach M. Tyrosinase is not detected in human catecholaminergic neurons by immunohistochemistry and Western blot analysis. JOURNAL OF NEURAL TRANSMISSION. SUPPLEMENTUM 2007:51-5. [PMID: 17982878 DOI: 10.1007/978-3-211-73574-9_8] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Catecholaminergic neurons of the primate substantia nigra (SN) pars compacta (SNc) and the locus coeruleus contain neuromelanin (NM) granules as characteristic structures underlying the pigmentation of these brain areas. Due to a phylogenetic appearance NM granules are absent in the rodent brain, but gradually become present in primates until they reach a maximal expression in humans. Although a possible mechanism of pigment formation may be autoxidation of the NM precursors dopamine or noradrenalin, several groups have suggested an enzymatic formation of NM mediated by tyrosinase or a related enzyme. Since tyrosinase mRNA is suggested to be expressed in the SN of mice and humans, we reinvestigated the expression of tyrosinase in the human SNc and the locus coeruleus at the protein level by immunohistochemistry and Western blot analysis, but could not detect tyrosinase in these brain regions.
Collapse
|
70
|
Gerlach M. Potenzielle Biomarker der Parkinson-Krankheit. AKTUELLE NEUROLOGIE 2007. [DOI: 10.1055/s-2007-980074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
71
|
Bartl J, Gruenblatt E, Gerlach M, Riederer P, Mori T, Ozawa H. Methylphenidate effects on cell growth and maturation in neuronal stem cells. PHARMACOPSYCHIATRY 2007. [DOI: 10.1055/s-2007-991828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
72
|
Schmitt AG, Hall FS, Kreutzfeldt M, Perona MTG, Ortega M, Hofmann M, Siemer M, Nietzer SL, Sora I, Uhl GR, Riederer P, Gerlach M, Lesch KP, Grünblatt E. The effect of methylphenidate treatment on the expression of synaptic vesicle proteins in a mouse model for Attention-Deficit/Hyperactivity Disorder. PHARMACOPSYCHIATRY 2007. [DOI: 10.1055/s-2007-991888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
73
|
Gerlach M, Hendrich A, Hueber R, Jost W, Riederer P, Winkler J, Woitalla D. Potenzielle Biomarker der Parkinsonkrankheit. AKTUELLE NEUROLOGIE 2007. [DOI: 10.1055/s-2007-970928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
74
|
Röser C, Renner TJ, Walitza S, Dempfle A, Nguyen T, Romanos M, Jacob C, Reif A, Schäfer H, Gerlach M, Warnke A, Lesch KP. GIRK2 – A novel candidate gene for attention deficit hyperactivity disorder. PHARMACOPSYCHIATRY 2007. [DOI: 10.1055/s-2007-991831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
75
|
Gerlach M, Hünnerkopf R, Rothenhöfer S, Libal G, Burger R, Clement HW, Fegert JM, Wewetzer C, Mehler-Wex C. Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. PHARMACOPSYCHIATRY 2007; 40:72-6. [PMID: 17447177 DOI: 10.1055/s-2007-972573] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
INTRODUCTION There are developmental and age-dependent differences in the pharmacokinetics and the pharmacodynamics of drugs in children and adolescents. Therefore, there is a need to carry out standardised studies to find out therapeutic ranges of plasma/serum concentrations in psychopharmacotherapy of children and adolescents. The aim of this prospective study was to examine the relationship between quetiapine serum concentration, treatment response, and side effects in a clinical setting to elucidate the age-specific therapeutic range of quetiapine in adolescents. METHODS Over a period of two years, therapeutic drug monitoring (TDM) was routinely performed in 21 adolescents (mean age was 15.9+/-1.5 years, 57% male) with psychotic disorders according to the guidelines of the AGNP TDM expert group. The psychopathology was assessed by using the Clinical Global Impression Scale (CGI) and the Brief Psychiatric Rating Scale (BPRS). Side effects were assessed by using the Dose Record and Treatment Emergent Symptom Scale (DOTES). Trough quetiapine concentrations were determined under steady state conditions after multiple-dose regimes (median 600 mg/day; range 100-800 mg/day). RESULTS There was a marked variability of the serum concentrations, ranging from 19-877 ng/ml. 40.8% of the determined values were below and 24.5% above the therapeutic range (70-170 ng/ml) recommended for adults. None of the patients had severe side effects. We found a weak correlation between dose and serum concentration of quetiapine and no relationship between serum concentration and treatment response. DISCUSSION There are several limitations of this study, and our results should therefore be interpreted with caution. Notwithstanding, differences in the ontogenesis of pharmacokinetics and pharmacodynamics may be the reason for the difference in the relationship between blood concentrations and therapeutic response to psychopharmaca in children, adolescents and adults. Further studies using larger samples, baseline assessment of psychopathology, definition of the treatment interval and investigation of clinically relevant interactions with various co-medications are warranted to improve the limitations of this pilot study.
Collapse
|